Compaction of very thin corneas from ultraviolet A riboflavin-vitamin E transepithelial cross-linking.

The purpose of the study was to determine the decrease in pachymetry of very thin corneas with advanced keratoconus due to corneal compaction from the ultraviolet-A (UV-A) irradiation phase of transepithelial (epi-on) cross-linking. Twenty removed corneal buttons were obtained from patients who underwent penetrating keratoplasty for advanced keratoconus. Removed corneal buttons selected from among the post-surgical specimens for this study had intact epithelium, no scarring or surgical cautery, endothelial cell density >2500 cells/mm2, and average pachymetry over the measured points of below 400 µm. Corneas were mounted in a Franz chamber. Each epithelial surface was soaked in isotonic riboflavin and D-alpha-tocopheryl polyethylene glycol 1000 succinate (Ribocross® IROMED Group, Italy) for 15 min. Pachymetry was measured at three points over both the shielded and unshielded corneal halves for each corneal button. Surfaces were then washed in saline to remove the Ribocross®. Shields from UV-A irradiation over half of each cornea were then fixed to stand 5 mm above the test corneas. UV-A irradiation using the custom fast cross-linking (CF-CXL) protocol was then performed for the typical 10 ± 1.5 min, for a total energy of 1.08 ± 0.6 J/cm2 after which pachymetry was re-measured. The average percent change in pachymetry was -0.43% ± 0.38% (maximum -1.06%) in the shielded half. Pachymetry change was -6.2% ± 2.2% (maximum 12%) in the cross-linked halves. In conclusion, we estimate that the change in corneal thickness from corneal compaction due to the cross-linking reaction itself was -5.8% ± 2.2%. Scanning electron microscopy of cross-linked corneal segments showed stromal fiber contraction.

Intra corneal ring segment implantation with lenticule assisted stromal augmentation for crosslinking in thin corneas.

PURPOSE: To evaluate the safety and efficacy of intra corneal ring segment (ICRS) implantation combined with crosslinking (CXL) using a Small Incision Lenticule Extraction (SMILE) lenticule for intraoperative stromal augmentation in thin corneas. OBSERVATIONS: The procedure was performed in three eyes of progressive keratoconus or post refractive surgery corneal ectasia, with a preoperative mean thinnest pachymetry of 389.34 ± 5.5 µm. Keratometry flattening (preoperative mean maximum keratometry of 63.17 ± 9.31D to postoperative mean maximum keratometry of 54.77 ± 9.47D) and improvement in spectacle corrected distance visual acuity (mean preoperative LogMAR 0.43 ± 0.19 to mean postoperative LogMAR 0.71 ± 0.26) was noted at three months, with stability at one-year postoperative visit. Demarcation line was demonstrated at a depth of 220.67 ± 8.32 µm. No significant endothelial cell loss was noted. CONCLUSIONS AND IMPORTANCE: Intraoperative stromal thickness augmentation using a lenticule obtained from SMILE allows safe and effective CXL in combination with ICRS in ultrathin corneas. This allows an alternative to lamellar keratoplasty for visual rehabilitation in such eyes.

Transepithelial corneal crosslinking in treatment of progressive keratoconus: 12 months' clinical results.

OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of transepithelial corneal collagen cross linking (TE-CXL) with modified riboflavin and accelerated UVA irradiance in thin corneas with pachymetry less than 400 microns at thinnest point, untreatable by epithelium off corneal collagen cross linking (CXL) in adult Pakistani population with progressive keratoconus. METHODS: This quasi experimental study included twenty six eyes of 26 patients with progressive keratoconus who underwent accelerated transepithelial CXL in Armed forced institute of ophthalmology with 12 months follow up. Modified riboflavin, ParaCel ((riboflavin 0.25%, Benzalkonium chloride, EDTA, Trometamol, hydroxypropyl methylcellulose) and vibeX Xtra (riboflavin 0.25%) (Avedro, USA)) were applied to cornea in two stages. Uncorrected and Corrected Distant Visual Acuities (UDVA, CDVA), spherical equivalent (SE), astigmatism, pachymetry at thinnest point (Pachy thin), apex keratometry (Kmax), simulated and steep keratometry (Sim K, steep K) were measured at baseline and at 3, 6 and 12 months post operatively. The cornea was then exposed to accelerated UVA irradiance of 9mW/cm2 for 10 min (total dose 30 mW/cm2). RESULTS: The mean age of the patient was 24.54±5.16 years. UDVA, CDVA, SE, astigmatism significantly improved at all postoperative test points (p=0.000, 0.004, 0.000, 0.004 respectively). Kmax and pachy thin were significantly reduced over baseline at 1 year (p=0.000, 0.004 respectively). Topographic indices Sim K and steep K did not show significant changes. No intra or post-operative complications were reported. CONCLUSION: Transepithelial accelerated CXL with modified riboflavin is a safe and effective procedure which halt disease progression in thin corneas with progressive keratoconus.

Photorefractive Keratectomy (PRK) is Safe and Effective for Patients with Myopia and Thin Corneas.

The aim of this study was to evaluate the long-term safety and efficacy of photorefractive keratectomy (PRK) for patients with myopia and thin corneas. In this retrospective case series, we included 74 eyes of 38 patients with myopia and central corneal thickness (CCT) < 550 µm who underwent PRK and had a mean postoperative follow-up period of four years. The following factors were evaluated: CCT, refraction, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), ablation depth, safety and efficacy indices (i.e., the ratio of the mean postoperative BCVA to the mean preoperative BCVA, and the ratio of the mean postoperative UCVA to mean preoperative the BCVA, respectively), and evidence of corneal ectasia (based on Orbscan topography images).The patients were aged 20 - 46 years (mean ±SD age, 28.18± 6.82 years). The mean ± SD pre- and postoperative CCTwas485.92 ± 9.27 µm and 434.84 ± 20.48 µm, respectively. The mean ± SD pre- and postoperative myopia was -2.77 D ± 1.51 and -0.24 ± 0.39 D, respectively, and the mean ± SD pre- and postoperative astigmatism was -0.82 D ± 0.99 and -0.37 ± 0.37 D, respectively. The mean pre- and postoperative BCVA and postoperative UCVA was 0.011 ± 0.03 Logarithm of the Minimum Angle of Resolution (log MAR), 0.003 ± 0.01 log MAR, and 0.054 ± 0.09 log MAR, respectively. The mean ± SD ablation depth, safety index and efficacy index was 54.34 ± 16.28 µm, 0.02 ± 0.12, and 0.11 ± 0.50, respectively. Regarding the postoperative corneal clarity, 72 eyes (97.3%) had a clear cornea (grade 0) and the remaining two eyes of one patient (2.70%) had a trace haze (grade 1). There was no evidence of corneal ectasia on any of the Orbscan topography images. Thus, among patients with myopia and thin corneas (<500 µm), PRK seems to be acceptable in terms of both safety and efficacy 4 years after surgery, based on the stability of postoperative refraction, visual acuity, and topographic outcomes, and outcomes based on the safety and efficacy indexes.

A short-term study of corneal collagen cross-linking with hypo-osmolar riboflavin solution in keratoconic corneas.

AIM: To report the 3mo outcomes of collagen cross-linking (CXL) with a hypo-osmolar riboflavin in thin corneas with the thinnest thickness less than 400 µm without epithelium. METHODS: Eight eyes in 6 patients with age 26.2±4.8y were included in the study. All patients underwent CXL using a hypo-osmolar riboflavin solution after its de-epithelization. Best corrected visual acuity, manifest refraction, the thinnest corneal thickness, and endothelial cell density were evaluated before and 3mo after the procedure. RESULTS: The mean thinnest thickness of the cornea was 408.5±29.0 µm before treatment and reduced to 369.8±24.8 µm after the removal of epithelium. With the application of the hypo-osmolar riboflavin solution, the thickness increased to 445.0±26.5 µm before CXL and recover to 412.5±22.7 µm at 3mo after treatment, P=0.659). Before surgery, the mean K-value of the apex of the keratoconus corneas was 57.6±4.0 diopters, and slightly decreased (54.7±4.9 diopters) after surgery (P=0.085). Mean best-corrected visual acuity was 0.55±0.23 logarithm of the minimal angle of resolution, and increased to 0.53±0.26 logarithm after surgery (P=0.879). The endothelial cell density was 2706.4±201.6 cells/mm(2) before treatment, and slightly decreased (2641.2±218.2 cells/mm(2)) at last fellow up (P=0.002). CONCLUSION: Corneal collagen cross-linking with a hypo-osmolar riboflavin in thin corneas seems to be a promising treatment. Further study should be done to evaluate the safety and efficiency of CXL in thin corneas for the long-term.

Customized epithelial debridement for thin ectatic corneas undergoing corneal cross-linking: epithelial island cross-linking technique.

Thin corneas with a minimum corneal thickness less than 400 µm after epithelial removal represent a contraindication to standard epithelium-off cross-linking (CXL) treatment due to a significant endothelial cell density decrease and potentiality of permanent haze development. Preoperative swelling of the cornea with hypoosmolar riboflavin solutions broadens the spectrum of CXL indications to thin corneas. However the iatrogenic swelling effect might not be durable throughout the CXL procedure increasing the risk of postoperative complications. The transepithelial CXL technique proposed for thin corneas demonstrated poor clinical results and mid- to long-term keratoconus instability. The epithelial island CXL technique with customized pachymetry-guided epithelial debridement was evaluated by means of in vivo laser scanning confocal microscopy, corneal topography, and clinical examination in a 1-year follow-up, in order to assess if it may be considered an alternative surgical option for keratoconic patients with thin corneas undergoing corneal collagen CXL. According to our clinical and in-vivo micro-morphological results the technique results safe, and efficacious in stabilizing progressive keratoconus and may be considered a valid option in the treatment of thin ectatic corneas alone or in combination with hypoosmolar or dextran-free riboflavin solutions.